Protagen to Use UniArray Platform to Discover Multiple Sclerosis Biomarkers for Biogen Idec

Protagen will use its UniArray protein-chip platform and expertise in autoantibody research to retrospectively analyze samples from a Biogen Idec clinical trial to identify predictive and response biomarkers associated with MS therapies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.